Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.10%96 EV-to-EBITDA is 13.49 as of Jul. 22, 2026, which is 19% below its 10-year median of 16.71. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 741 Drug Manufacturers companies, Recordati SpA ranks worse than 51.15% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Recordati SpA's enterprise value is €12,434 Mil.
Recordati SpA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €922 Mil. Therefore, Recordati SpA's EV-to-EBITDA for today is 13.49.
The historical rank and industry rank for Recordati SpA's EV-to-EBITDA or its related term are showing as below:
MIL:REC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.83 Med: 16.71 Max: 23.7
Current: 13.49
During the past 13 years, the highest EV-to-EBITDA of Recordati SpA was 23.70. The lowest was 12.83. And the median was 16.71.
MIL:REC's EV-to-EBITDA is ranked worse than 51.15% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.24
vs MIL:REC: 13.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Recordati SpA (MIL:REC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Recordati SpA's PE Ratio (TTM) for today is calculated as:
Recordati SpA's share price for today is €51.35.
Recordati SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.255.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Recordati SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Recordati SpA's EV-to-EBITDA falls into.
Recordati SpA's current Enterprise Value is €12,434 Mil.
Recordati SpA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €922 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a EV-to-EBITDA of 13.49 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Recordati SpA. This is 19% below median its historical median of 16.71. Over the past decade, Recordati SpA's EV-to-EBITDA has ranged from 12.83 to 23.70. According to the industry distribution chart, Recordati SpA ranks #379 out of 741 companies in the Drug Manufacturers industry, placing it in the top 51.1%.
Is Recordati SpA's EV-to-EBITDA too high?
Recordati SpA's current EV-to-EBITDA of 13.49 is 19% below median its 10-year median of 16.71. Over the past 10 years, this metric has ranged from a low of 12.83 to a high of 23.70. The Drug Manufacturers industry median EV-to-EBITDA is 13.24. Recordati SpA's value of 13.49 is 1.9% above this industry median. Based on the distribution chart, Recordati SpA ranks #379 out of 741 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #379 out of 741 companies for EV-to-EBITDA. This places Recordati SpA in the lower half of its industry. The industry median EV-to-EBITDA is 13.24. Recordati SpA's value of 13.49 is 1.9% above this benchmark. Historically, Recordati SpA's own EV-to-EBITDA has ranged from 12.83 to 23.70 over the past decade. While the company's 10-year median is 16.71 vs. the industry median of 13.24, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.24, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current EV-to-EBITDA of 13.49 is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Recordati SpA. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current EV-to-EBITDA is 13.49, which is 19% below median its own 10-year median of 16.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.90, compared to a current price of €51.35 — trading 15.7% below its estimated fair value. The current EV-to-EBITDA is 13.49, which is 19% below median its 10-year median of 16.71 and 1.9% above the Drug Manufacturers industry median of 13.24. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current EV-to-EBITDA is 13.49 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.35 is trading 15.7% below its estimated GF Value™ of €60.90.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
EV-to-EBITDA: 13.49 (19% below median its 10-year median of 16.71)
GF Value™: €60.90 vs. price of €51.35 (15.7% below fair value)
Industry Position: 1.9% above the Drug Manufacturers median (#379 of 741)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
